Anixa Biosciences Advances Ovarian Cancer Therapy to Highest Dose

This latest milestone in the dose-escalating trial involves administering 1×10⁷ CAR-positive cells per kilogram following lymphodepletion. Researchers have reported no dose-limiting toxicities in any cohort up to the previous 3x10⁶/kg level, suggesting a favorable safety profile for the experimental treatment, known as liraltagene autoleucel.

Clinical data indicates encouraging signs of efficacy among a population typically facing poor prognosis. Five patients have survived more than one year post-treatment, with one individual surpassing two years. Dr. Amit Kumar, CEO of Anixa Biosciences, noted that these survival metrics are significant for patients who have already exhausted multiple prior lines of therapy. Unlike traditional cell therapies that rely on antibody fragments, this CER-T technology utilizes the natural ligand of the FSHR receptor to bind to cancer cells, sparing healthy tissue. The trial continues to monitor safety and long-term outcomes as enrollment proceeds.